Cannabinoid hyperemesis syndrome (CHS) is characterized by recurrent episodes of severe nausea, vomiting, and abdominal pain and is associated with prolonged, frequent cannabis use. This webinar will review the clinical features of CHS, current knowledge about its development and risk factors, and approaches to acute treatment. Particular attention will be given to cannabis cessation as the only established way to prevent recurrent episodes, as well as the challenges people may experience when attempting to stop using cannabis.
Participants will also examine the rise in CHS-related emergency department visits, differences across demographic groups, and the possible contribution of changing patterns of cannabis use and product potency. The presentation will conclude with practical ways prevention professionals can increase awareness, communicate effectively about CHS, and connect affected individuals with appropriate medical and behavioral health resources.
Objectives
Upon completion of this webinar, participants will be able to:
- Define cannabinoid hyperemesis syndrome and identify its characteristic symptoms, clinical course, and recognized risk factors
- Distinguish the acute medical management of CHS from the role of cannabis cessation in preventing recurrent episodes
- Describe common barriers to cannabis cessation and identify supportive, nonstigmatizing approaches for engaging affected individuals
- Summarize trends in CHS-related healthcare encounters, including differences by age and other demographic characteristics
- Identify ways prevention professionals can incorporate CHS awareness, education, and referral into their work